Maximum Tolerated Dose Nonrandomized, COMPLETED 2008-03-01 TABULATIONS MedDRA of SDSP-002 Administered Control None, LEGACY (Adverse Events) Intravenously in Patients Single Group, 10.0 with Advanced Solid Open ANALYSIS Tumors Safety, LEGACY WHO-DD Treatment (Medications) 2007-03 Phase 1 Interventional Studies - Advanced Hematological Malignancies SDSP-002 Administered Randomized, COMPLETED 2008-06-01 TABULATIONS MedDRA Control None, LEGACY (Adverse Events) Intravenously in Patients Parallel Assignment, 10.0 with Advanced Single Blind, ANALYSIS Hematological Pharmacokinetic, LEGACY WHO-DD Malignancies Treatment (Medications) 2007-03 Phase 1 Interventional Studies - Advanced Non-hematological Malignancies
Maximum Tolerated Dose of SDSP-002 Administered Intravenously in Patients with Advanced Solid Tumors Nonrandomized, Control None, Single Group, Open Safety, Treatment COMPLETED 2008-03-01 TABULATIONS LEGACY ANALYSIS LEGACY MedDRA (Adverse Events) 10.0 WHO-DD (Medications) 2007-03 Phase 1 Interventional Studies - Advanced Hematological Malignancies SDSP-002 Administered Intravenously in Patients with Advanced Hematological Malignancies Randomized, Control None, Parallel Assignment, Single Blind, Pharmacokinetic, Treatment COMPLETED 2008-06-01 TABULATIONS LEGACY ANALYSIS LEGACY MedDRA (Adverse Events) 10.0 WHO-DD (Medications) 2007-03 Phase 1 Interventional Studies - Advanced Non-hematological Malignancies
SDSP_Example_Oncology.docx